Celldex Therapeutics Inc. (NASDAQ:CLDX) shares were trading slightly lower in premarket trading on Friday after the company announced Thursday that it will discontinue developing barzolvolimab for moderate to severe atopic dermatitis (AD) after the drug failed to meet primary and key secondary efficacy goals in a Phase 2 trial.
While barzolvolimab showed some clinical benefit, results fell short of the company’s internal threshold for continued investment.
Phase 2 Trial Design and Efficacy Miss
Researchers randomized 131 patients to receive subcutaneous barzolvolimab injections of 150 mg or 300 mg every four weeks, following a 450 mg loading dose, or a placebo during a 16-week controlled period.
Afterward, patients entered a 16-week active treatment phase where placebo recipients switched to an active dose.
At Week 16, neither dose achieved statistical significance on the primary endpoint, which measured the percent change from baseline in the weekly average of daily Peak Pruritus Numerical Rating Scale (PP-NRS) itch scores versus placebo.
Patients taking the 300 mg dose posted a 29.2% score reduction, while the 150 mg group saw a 16.2% drop, compared with a 19.5% reduction for placebo.
Key secondary measures, including Eczema Area and Severity Index (EASI) improvements and Investigator’s Global Assessment (IGA) scores of 0 or 1, also failed to meaningfully separate from placebo.
Extending treatment through Week 32 produced no additional efficacy gains.
Safety Profile and Future Pipeline Plans
Barzolvolimab, a humanized monoclonal antibody that targets the KIT receptor to deplete mast cells, maintained a favorable safety and tolerability profile consistent with earlier trials.
Both doses rapidly and profoundly suppressed serum tryptase throughout the treatment period, indicating systemic mast cell depletion.
Despite ending the AD program, Celldex continues advancing barzolvolimab across other mast cell-driven diseases.
The company anticipates submitting a Biologics License Application (BLA) for chronic spontaneous urticaria in 2027, is actively enrolling patients in Phase 3 studies for cold urticaria and symptomatic dermographism and plans to announce additional indications by year-end.
In July, Celldex Therapeutics ended its Phase 2 trial of barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.
The trial’s primary goal was to observe a four-point or greater improvement on the worst itch numeric rating scale at the 12-week mark.
The percentage of patients reaching this milestone showed no meaningful differentiation from the placebo group.
CLDX Price Action: Celldex Therapeutics shares were down 0.25% at $27.89 during premarket trading on Friday, according to Benzinga Pro data.
Photo: Pavel Kapysh / Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.




